CRi, 3DHISTECH align on digital pathology

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
Cambridge Research & Instrumentation (CRi) has agreed to distribute 3DHISTECH’s suite of digital slide scanners and software applications in North America, develope and distribute a next generation of product offerings.

George Abe, president and CEO of the Woburn, Mass.-based CRi, said that digital pathology technologies were providing important infrastructure for emerging molecular diagnostic approaches based on disease-related biomarkers.

3DHISTECH, based in Budapest, Hungary, offers a broad line of digital pathology products, scanners and software for slide viewing, quantitation, telemedicine, and image management, said CRi.

Manjula Puthenedam, PhD,

Related Content

Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.